How does PRE's Q4 outlook compare to industry peers?

Prenetics Global (PRE) is expected to report a positive earnings per share (EPS) of $0.04 for Q4 2024, while its industry peers, Aprea Therapeutics (APRE) and Green Plains (GPRE), are estimated to report negative EPS of -$0.66 and -$0.23, respectively. This indicates that PRE is likely to perform better than its peers in the upcoming quarter. Additionally, PRE's positive last change of 1.12% compared to GPRE's negative last change of -4.3% suggests a more favorable outlook for PRE within the industry.